Day 1 :
Keynote Forum
Antonio J Ribeiro
University of Coimbra, Portugal
Keynote: IMPUCT- Technological development of polymeric implants for extended release of drugs
Time : 09:30-10:30
Biography:
António J Ribeiro is Professor of Pharmaceutical Technology at the Faculty of Pharmacy of Coimbra. In 1997 he obtained his PhD degree from University Paris V in Pharmaceutical Technology specializing in microencapsulation. He received graduate training in both Europe and North America, has held academic positions in several Faculties of Pharmacy of Portugal. He is a specialist on pharmaceutical by training and has been working in the design and testing of biotechnology/ biopharmaceuticals delivery systems. He is the author of more than 100 publications including more than 60 peer review publications, 5 books’ chapters and 3 patents.
Abstract:
IMPUCT is the development of technology for the manufacture of polymeric matrix implants for extended release of drugs. Hot-melt extrusion was the selected manufacturing process to obtain the implants and the polymers used belong to lactate/glycolate copolymers group as they are biodegradable and because of their plastic and thermal properties. IMPUCT aimed to test its applicability through the development of a prototype implant with a frequency of administration of not less than 14 days, ideally once a month administration, Pre-clinical results showed efficacy and developed analytical methods for determination of “in vitro” biologic activity of the active substance during processing revealed the maintenance of active substance activity. Thus, IMPUCT develops the technology to achieve the necessary requirements so that the production of implants could be, in a subsequent phase, transposed to an industrial scale and that the developed exenatide implant is included in a clinical development program in humans.
Break: Networking and Refreshments with Group Photo @ 10:30-11:00
Keynote Forum
Nadine Ziad Zeinab
Johns Hopkins International, Lebanon
Keynote: Managing patients on opioid therapy: A pharmacist perspective
Time : 11:00-12:00
Biography:
Nadine Ziad Zeinab is an active member at the European Society of Oncology Pharmacy (ESOP) and a part of the educational board at the European Specialization in Oncology Pharmacy (EUSOP). Completed the ASHP Pain Management Certificate, ASMP-ISMP Medication Safety Certificate and Clinical Skills for International Pharmacist. Completed MS in Pharmacology and Therapeutics at the American University of Beirut by 2013, and a BS in Pharmacy at the Lebanese International University by 2009. Currently practicing as the senior clinical oncology pharmacist at Clemenceau Medical Center Affiliated with Johns Hopkins International. Applied as a PhD candidate in Clinical Pharmacy at Near East University.
Abstract:
Managing Patients on Opioid Therapy: A Pharmacist Perspective. One of the most challenging clinical roles that pharmacist can play is the intervention in setting the pharmaco-therapeutic plan for the management of pain. The understanding of pain pathophysiology and types dictates the treatment option. Clinical Pharmacist must be able to assess the type of pain, to understand the available treatment options of con-analgesics and opioids, be able to safely dose and convert from one opioid to another, and monitor for opioid related side effects. Opioids are highly prescribed in moderate to severe pain as per the WHO analgesic ladder. Clinical Pharmacist should be knowledgeable enough about opioid dosing calculation and conversion from one opioid to another, and the selection of the opioids based on patient and opioid related factors. The role of the clinical pharmacist in the multi-disciplinary pain management has increased to optimize the safe use of opioids.
- Bioavailability and Bioequivalence | Pharmaceutical Sciences | Pharmaceutical Technology | Clinical Pharmacy | Drug Discovery and Design | Novel Drug Delivery Systems | Pharmaceutical Sciences | Pharmacy
Location: Dubai, UAE
Chair
Heyam Saad Ali
University of Khartoum, Sudan
Session Introduction
Kavitha Jayaseelan
SRM College of Pharmacy, India
Title: Bioavailability, bioequivalence & Pharmacokinetic study - regulations, design, conduct and analysis
Time : 12:00-12:30
Biography:
Kavitha J, working as Associate Professor in SRM College of Pharmacy, SRMIST for the past 11 years. She has completed her Ph.D in the field of Pharmacy, with her specialization in Pharmaceutical Analysis. During her study period she was well trained in handling advanced instruments like UV, HPLC, HPTLC, FT-IR, LCMS and to conduct bioequivalence studies. She is specialized in food and cosmetic analysis. She has published more than 20 papers in reputed journals and has been serving as a reviewer of many reputed journals.
Abstract:
The therapeutic effectiveness of a drug depends upon the ability of the dosage form to deliver the medicament to its site of action at a rate and amount sufficient to elicit the desired pharmacological response. This attribute of the dosage form is referred to as physiological/ biological availability or simply as Bioavailability (BA). The expected in-vivo biological equivalence of two proprietary preparations of a drug is coined as Bioequivalence (BE). Several in-vivo and in-vitro methods are available to measure the quality of the product. The basic in-vivo bioavailability study is designed in such a manner that the formulation effect should be distinguished from other effects. Typically, a two-period, two-sequence crossover design or a parallel design is usually employed. Prior to the onset of a BA/ BE study, the study parameters such as volunteers recruitment, study dose, fixation of sampling points, moieties to be measured in the collected biological samples, pharmacokinetic parameters, Good Clinical Practice (GCP) requirements etc., needed by the pharmaceutical industry to carry out the study with the approval of the institutional ethical review board, henceforth to file the new drug application (NDA) or an abbreviated new drug application (ANDA) were assessed. A major change in the policies and procedures have occurred due to the recent harmonization in the regulatory requirements for BA/ BE studies. Selection of ideal sample preparation technique for processing the bioanalytical samples is a crucial step, as the complex matrices may seriously interfere with the quantification of the target analytes. A well-characterized and fully validated analytical methodology needs to be employed for the quantification of drugs and their metabolites in biological samples. The final report of a BA/ BE study gives the complete documentation of the above measured parameters complying with the declaration of Helsinki and GCP rules.
Alp Yildiz
Yildirim Beyazit University, Turkey
Title: Rubber band ligation on internal hemorrhoid treatment as a safe and effective option
Time : 12:30-13:00
Biography:
Alp Yildiz born in Kutahya in 1983, has completed medical degree on Gazi University School of Medicine, has completed her PhD as General Surgery Specialist at 2015. He is one of the leading surgeons on colorectal surgery of a tertiary care university hospital in capital city Ankara. He has published more than 20 papers in reputed journals and has been serving as colorectal surgeon in Yildirim Beyazit University, Yenimahalle Training and Research Hospital.
Abstract:
Rubber band ligation is established as one of the most important, cost-effective and commonly used treatments for first- to third-degree internal hemorrhoids, causing fibrosis, retraction, and fixation of the hemorrhoidal cushions. In this study we evaluate the safety of the procedure according to complication rates. 134 patients with Grade 2 internal hemorrhoids included the study. All patients underwent single or two quadrant rubber band ligation under local anesthesia. Intraoperatively 21 patient developed mild bleeding, 1 patients developed massive bleeding postoperatively. No patient developed thrombosed hemorrhoids , 11 patients developed urinary retention needing catheterization, 51 patients developed mild pain postoperatively. 14 patients developed vasovagal symptoms, in 1 patient slippage of bands occured. Pelvic sepsis and death not occured. Haemorrhoids are very common, affecting as many as 1 in 4 of the population and resulting in a significant community and hospital practice burden. Over 20,000 haemorrhoidal procedures are carried out in the UK each year. Treatment options for haemorrhoids are varied; however, the evidence base for many of these options has, until recently, been poor. Despite the poor scientific substantiation, some of these treatment options have stood the clinical test of time. However, many new options have been introduced since the turn of the century. There is recent scientific support for some of these newer options that allow an evidence-based update to management. In this study our results showed that rubber band ligation is a safe and effective option Grade 1 and 2 internal hemorrhoids in proper cases.
Break: Lunch @ 13:00-14:00
Agris Auce
Rigas Stradins University, Latvia
Title: Freshwater Sapropel as raw material in pharmaceutical production
Time : 14:00-14:30
Biography:
Agris Auce, studied physics in the University of Latvia, graduated in 1989. PhD in Nuclear Physics in 2004 from the Uppsala University, Sweden for the experimental work with the Gustaf Werner Cyclotron in the The Svedberg Laboratory, Sweden and iThemba medical and isotope production cyclotron in South Africa. In 2006-2008 was scientific leader for Latvia cyclotron project intended for the production of medical isotopes. In 2000 -2013 with partners developed SIA Silvanols, the most successful pharmaceutical startup company in Latvia specializing in natural remedies based products. Now leading researcher at Riga Stradins University and University of Latvia.
Abstract:
Sapropel is traditional remedy applied topically in skin care and other health procedures. Sapropel forms in shallow waters by slowly decomposing organic sediment. There is a recent growth in its use in medicine, rehabilitation and skincare. Extraction of active ingredients from sapropel has been reported in literature. Raw material control and quality assurance have to be developed for sapropel for its use as raw material in medicine and pharmacology. Freshwater sapropel from freshwater lakes in Latvia was tested and standardized for the use in medicine and pharmaceutical industry. Geological survey data of Latvia lakes (ezeri.lv) were used to select 5 lakes. Site selection criteria were sapropel deposits depth, hydrological regime, exposure to industry and agriculture. 105 samples were collected. Organoleptic testing (look, consistence and smell, coarse composition test), measurements of heavy metal and pesticide residue, bacteriological test and pH were used for standardizing and describing of sapropel. Pb, Cd, Co, Ni, Cu were present well below acceptable level. Some samples had DDT residues. pH level is between 7 – 8. The concentration of humic and fulvic acids in samples varies between different mining sites and
sapropel strata levels. Storage at 4C in dark and without oxygen was sufficient for preserving sapropel.
Conclusion: After the extraction site is certified sapropel can be used as a quality assured raw material for medicine and pharmacology. The research was co-financed by project "Analysis of characteristics of medical sapropel and its usage for medical purposes and elaboration of industrial extraction methods", No.1.1.1.1/16/A/165.
Norah Mobarki,
College of Medicine University of Sharjah, UAE
Title: The role of oxysterols as selective estrogen receptor modulators (serms) at promoting tumor growth in adrenocortical carcinoma
Time : 14:30-15:00
Biography:
Norah is a Senior Toxicologist at Central Military Lab & Blood Bank CML&BB in Prince Sultan Military Medical City PSMMC. Norah's primary specialist is Chemistry. Then, she got a higher diploma in Sciences and Management from the Dublin International Foundation College DIFC, which is one of the NCUK partner Colleges. Norah is an Alumni from College of Sciences at National University of Ireland, Galway NUIG with a master degree of Sciences in Toxicology. She is a member of the following: Society of Forensic Toxicology SOFT, Saudi Society for Clinical Chemistry SSCC and Saudi Society for Clinical Laboratory Sciences. Currently, Norah is working on Forensic and Clinical Toxicology in a toxicology reference laboratory in Saudi Arabia. Norah is handling the samples and cases for patients and Military clients with excellence and considerable experience.
Abstract:
Adrenocortical carcinoma (ACC) is an aggressive and rare endocrine malignant with very limited treatment options at present. Besides, its recurrence rate is high and can occur in a short following period. ACC is a steroidogenesis cancer produces steroid hormones, that all share cholesterol as a key building unit. Thus, cholesterol active metabolites (oxysterols) could potentially interfere these steroids pathways and produce different cellular modifications through different receptors, included ERs. In ER+ breast cancer cells, oxysterols (i.e. 27Hydroxy Cholesterol) promote cell proliferation through estrogen receptor alpha ERα. Therefore oxysterols as selective estrogen receptor modulators (SERMs), we hypothesized that they could act similarly via ERs in ACC cells (H295R) and promote cell growth. In this study, H295R cells were treated for 24-h with (27HC) at various doses (0, 10, 20, 40, 80 uM) alone or combined with hydroxyl-tamoxifen (10uM OHT) or/ and 10nM 17-β estradiol (E2) to investigate the proliferative effect. The same treatment scheme was applied on MCF7 breast cancer cells. The principle experimental technique was crystal violet staining in which cells growth was measured via spectrophotometer at 550nm. The finding showed that 27HC plays a role at stimulating cell division on H295R cells, however, this effect is being further enhanced in the presence of other agents: E2 and OHT. For MCF7 control cells, the outcomes were correlated to a previous work that 27HC stimulates cell proliferation and OHT inhibits tumor formation. Overall, 27HC showed an expected effect, whereas, OHT unexpectedly induce cell density. Therefore, further work should consider the unexpected stimulatory effect of OHT and its mechanistic pathway, prior to suggesting it as an anti-estrogenic drug in ACC setting.
Priya Deivasigamani
SRM College of Pharmacy, India
Title: Design, synthesis and evaluation of some novel substituted benzene sulphonamide derivatives as anti-inflammatory agents
Time : 15:00-15:30
Biography:
Priya D, working as Associate Professor in SRM College of Pharmacy, SRMIST for the past 07 years. She is pursuing her Ph.D. in the field of Pharmacy, with her
specialization in Pharmaceutical Chemistry. Her area of interest is Molecular modeling and docking software's studies and has many publications related to her
field. She has published many research and review articles in reputed National and International Journals. She has guided 06 UG projects and 02 PG projects.
Abstract:
Benzene Sulphonamide is an important pharmacophore in modern drug discovery and are one of the least expensive chemotherapeutic agents. In order to evaluate the synthesized compounds as COX-2 inhibitors a series of compounds with definite IC50 values were selected as the dataset by using Padel. The obtained IC50 values are then converted into corresponding pIC50. Among the compounds selected 75% were utilized as a training set and remaining 25% were chosen as a test subset for validating the QSAR model. The model is extensively validated according to OECD standards, so that its robustness, stability, low correlation of descriptors and good predictive power are proven. In addition, it is found that the model fit is not the product of a random correlation. Based on the model obtained the series of designed compounds were synthesized. The structures of the synthesized compounds were elucidated by IR spectra and were then evaluated for their anti-inflammatory activity using carrageenan- induced paw edema method against the standard Diclofenac. In silico studies were carried out to define the interaction between the synthesized compounds with COX-2 enzyme. Results from in vivo and in vitro studies of synthesized compounds were found to be in good correlation with in silico study.
Break: Networking and Refreshments @ 15:30-16:00
Burak Gokay Yıldırım
EskiÅŸehir Osmangazi University, Turkey
Title: New nano technological approaches and research in the treatment of periodontal disease
Time : 16:00-16:30
Biography:
In 2016, he graduated from the Faculty of Dentistry of Atatürk University. He started his periodontology residency at Bülent Ecevit University. He is currently working as a research assistant at EskiÅŸehir Osmangazi University.
Abstract:
There have been various efforts in designing different drug delivery systems (DDSs) for periodontal diseases based on the functionalized nanomedicines. The aim of this study is to review the recent treatment of periodontal diseases with nanomaterials. Moreover, this study also focuses on basic principles of utilizing the nanomaterials to create better DDSs for treatment of periodontal diseases. This type DDSs have numerous advantages include improved efficacy, reduced toxicity and improved patients compliance and convenience. Novel DDSs are being introduced for the treatment of periodontal diseases. Examples of these DDSs can be listed as follows: films, nanogels, nano-micro particles, liposomes, nanofibers, quantum dots, nanopores, nanotubes, nanofillers, nanocomposites, scaffold etc. Many drugs used in periodontal diseases have been encapsulated into these systems. Examples of these encapsulated drugs can be listed as follows: tetracycline, doxycycline, minocycline, metronidazole etc. The treatment of periodontal disease with new DDSs mentioned at above section, represent a step forward toward successful long-term healing by increasing the treatment efficacy, specificity, tolerability and therapeutic index of encapsulating drugs. Main treatment strategies in periodontal disease with nanomaterials are removal of microbial biofilm, delivery of novel active compounds for host inflammatory response modulation and supporting regeneration of periodontal tissue. By the improvement in the periodontal DDSs, it can be emphasized that the nanotechnology which is antibiotic free, mucoadhesive, biodegradable has a huge opportunity for designing a novel, low dose, and effective treatment. It will make possible for Nano dentistry to maintain the comprehensive oral health by employing nanomaterials, biotechnology which includes the tissue engineering and dental nanorobotics. Even though this technology is at a primary stage, it has already made a profound clinical and commercial impact in the field of dentistry.
Kalaiselvi S
SRM College of Pharmacy, India
Title: Development of fast dissolving tablets of Almotriptan Maleate Using superdisintegrants
Time : 16:30-17:00
Biography:
Kalaiselvi.S from SRM Institue of Science and Technology, Kattankulathur, Tamilnadu completed her under-graduation B.pharmacy with 92 percentage and
undergoing my post-graduation M.pharmacy in SRM Institute of Science and Technology, India.
Abstract:
The studies were undertaken to develop fast dissolving tablets of almotriptan maleate. Almotriptan is a second generation highly selective 5-HT 1B/1D agonist used to alleviate the migraine pain. Almotiptan is well-absorbed after oral administration, with an absolute bioavailablity of about 70% and elimination half-life of 3-4 hours. The fast dissolving tablets were formulated to enhance the drug dissolution characteristics and thereby to achieve quick onset of action. The tablets were prepared using various proportions of sodium starch glycolate, croscarmellose sodium, crospovidone as superdisintegrants. Magnesium stearate was used as glidant and aerosil was used as lubricant. The final weight of tablet was adjusted to 200mg using dicalcium phosphate as directly compressible vehicle. A control tablet was prepared using all excipients except superdisintegrants. Saccharin sodium and mannitol was used as sweeting agents. From the infrared spectral analysis, it was understood that there was no significant interaction between the drug and excipients used in the formulation. The drug content in all the tablet batches was found to be uniform. The friability test of all the formulation was found to be less than 1% which indicates the resistant to abrasion. The hardness of prepared tablets ranged from 3.5-4.5 kg/ cm2. The prepared tablets were found to be uniform in weight and weight variation was within the limit of ±7.5%. The results of dissolution studies showed the rapid and fast dissolution of almotriptan maleate when compared to the control tablet. Among the superdisintegrants used, crospovidone 4% gave fastest drug release when compared to other batches.
Francisco Veiga
University of Coimbra, Portugal
Title: Preparation and characterization of mixed polymeric micelles as a versatile strategy for meloxicam oral administration
Time : 17:00-17:30
Biography:
Francisco Veiga presently he is working as a professor in University of Coimbra, Portugal.
Abstract:
Introduction: Nowadays, a significant number of drugs getting approvals have poor biopharmaceutical properties. One example is meloxicam (ME), a highly potent nonsteroidal anti-inflammatory drug. New drug delivery strategies have
been developed in order to overcome this issue and nanotechnology represents one of the most popular strategies. Among nanotechnology, polymeric micelles are emerging as a new Nanoplatform in several therapeutic applications such as increasing water solubility, permeability and consequently, the oral bioavailability of the drugs.The aim of this work was to demonstrate the advantages of using mixed polymeric micelles (Pluronic® F68 and P123) to encapsulate ME, when compared with the drug alone, and to characterize the prepared micelles. Morphology was studied by transmission electron microscopy. 5 μL of freshly prepared micellar dispersions were placed on Formvar and allowed to dry for 5 min. To unveil the usefulness of such formulations concerning physical stability, formulations FM1-FM5 and ME were dissolved in enteric and gastric medium. After 1 and 2 h it was quantified ME in gastric medium and after 3 and 4 h it was quantified ME in enteric medium. Quantification was performed using an UV spectrophotometer and absorbance taken at 363 nm. To determine encapsulation efficiency, FM1-FM5 were quantified immediately after preparation. Later on, micellar suspensions were centrifuged at 3000 g for 15 min using Amicon® Ultra 4 Centrifugal filter units, the supernatant was quantified and EE calculated based on the following equation:EE(%)=(conc in micelles-conc in supernatant)/(conc in micelles) x100. Finally, cytotoxicity of formulations was assessed in Caco-2 cells by Alamar Blue assay, performing a screening of crescent concentrations for each formulation. Micelles were found to present small sizes andspherical shape, with ME forming a circular line near to the micelle´s surface. All formulations significantly increased ME physical stability in enteric medium. In gastric medium, despite of FM2 and FM3 showed the best results, all the other formulations showed a significant increase on stability. With the exception of FM1, all formulations demonstrate high EE % (FM1:35.544±3.919, FM2: 93.162±1.071, FM3: 90.663±1.805, FM4: 89.840±1.991, FM5: 86.607±2.134). Finally, FM3 revealed no cytotoxicity in concentrations ranging from 0.625 to 5% and FM2 revealed no cytotoxicity in concentrations ranging from 0.625 to 2.5%. FM2 and FM3 seem to be promising formulations to efficiently encapsulate drugs with low water solubility, as meloxicam.
Asad Khan Tanoli
University of Karachi, Pakistan
Title: Metal complexes from bishydrazones ligands; design, characterization and antileishmaniasis activities
Biography:
Dr. Asad Khan Tanoli started his career as a lecturer in University of Karachi since 2008. He received his PhD degrees from the University of Karachi, Pakistan. Recently, serving as Assistant Professor in the same university. He is an author of 21 peer-reviewed papers and 2 book chapters. His major contribution belongs in to the field of bioinorganic and medicinal chemistry. Dr. Asad is working as an Editorial Board member of two journals.
Abstract:
Leishmaniasis, a complex vector-borne disease instigated by more than 20 species of the protozoan genus Leishmania and hosting more than 300 million people. The limited therapeutic options and the increasing drug resistance against the conventional anti-leishmanial drugs, urge the need for development of new leishmanicidal agents. In the recent era, antiparasitic properties of metal complexes have been widely studied. A variety of hydrazones derivatives along with their metal complexes have been reported as antiparasitic agents. In this work, coordination complexes from first series of transition metals were synthesized using hydrazone derivatives as bidentate ligands. All the synthesized compounds have been characterized by using different techniques i.e. elemental analysis (CHN), SEM, EI-Mass, 1-H NMR, 13C NMR, UV–Visible spectroscopy, IR spectroscopy, ESR and magnetic susceptibility measurements. Based on the analytical and spectral data octahedral geometry have been assigned to all the complexes. Synthesized metal complexes were evaluated for their in vitro antiparasitic potential. Metal complexes were found to be good leishmanicidal agents.
- Pharmaceutical Sciences | Pharmaceutics | Novel Drug Delivery Systems | Pharmaceutical Technology | Pharmacy | Pharmacology and Toxicology | Pharmaceutical Care | Drug Discovery and Design | Clinical Pharmacy
Location: Dubai, UAE
Chair
Heyam Saad Ali
University of Khartoum, Sudan
Session Introduction
Rajender Reddy Leleti
Sambi Pharmaceuticals, India
Title: Innovative methods for synthesis of novel pharmacophores
Time : 11:30-12:00
Biography:
Rajender Reddy Leleti, CEO of Sambipharma, He has over 25+ years of scientific research experience in process development, process optimization, cost effective and safer route selection, synthesis of complex NCEs/APIs, total synthesis of biologically active molecules at Novartis Pharmaceuticals, Piramal Pharma Solutions, Sai Life Sciences, Harvard University, RWTH University and Scientifically trained by Nobel Laureates. He have published over 90 publications and patent. He is also a member of Ad-Hoc Board of Studies, Sardar Patel University, Gujarat and member of Scientific Advisory Council, Indrashil University, Gujarat.
Abstract:
In the modern drug discovery, several innovative models were introduced such as scaffold hopping, escape flatland, conformational restriction and chemical equivalents. It has gained a significant recognition in the scientific community. In this perspective, scientists are currently looking for novel attractive molecules for the synthesis and exploration in the drug discovery. The development of the new methodologies for key pharmacophore motifs will be accelerate the designing process of active APIs. In the recent years, we have designed and demonstrated several new asymmetric methodologies for following key pharmacophore motifs.
Heyam Saad Ali,
University of Khartoum, Sudan
Title: Targeted liposomes and theranostic applications in cancer treatment
Time : 12:00-12:30
Biography:
Prof. Dr. Heyam Saad Ali, M. Pharm., and Ph-D. currently joined University of Khartoum, faculty of pharmacy, Sudan Prof. contributed more than 70 articles to reputed international scientific journals and conferences, in different conventional, controlled and targeted drug delivery systems in pharmaceutical product development. She has been invited as speaker to numerous International conferences .Reviewer and member of editorial board of many international journals.
Abstract:
Traditional chemotherapy is not recommended in the clinical settings due the severe complications patients exercising during use. Some of these complications include: severe systemic problems, [MDR] and toxicity. The reasons of such off-targeted side effects are due to the poor specificity and selectivity of drug deliver systems to target the biological molecule in the site of cancerous tissue. Therefore, advancement in the targeted delivery systems using nanotechnology techniques and Nano carriers are the area of interest and attention of many researchers, scientists and academia’s. Currently, significant developments, approaches and strategies are utilized to target the cancerous tissue. From these strategies of targeting the drug delivery is using Nano carriers such as liposomes, polymer nanoparticles, dendrimers etc. In addition to strengthen the conjugation to the selected extracellular and intracellular biological molecules such as receptors, carbohydrate determinant antigen, antibodies etc. Further more, utilizing the biological microenvironment surrounding the cancerous tumor, such as in passive targeting, and PEGylated liposomes to overcome the biological barriers through its journey to the cancerous tissue or cells. Moreover, the Nano carrier can be functionalized with directed ligands [active targeting] and physical responsive stimuli using the relevant techniques for a particular application. This presentation will high lights various current and recent strategies to overcome the limitation of conventional chemotherapy. However, nanotechnology is still in infancy since a lot of toxicity of the used nanomaterials and ethical issues have not been resolved yet. cell receptors via surface-attached ligands that direct drug uptake into tumor cells or tumor-associated stromal cells, and so can increase the selectivity of drug delivery.
Break: Lunch @ 12:30-13:30
A Alper Ozturk,
Anadolu University, Turkey
Title: Current medical nanotechnology approaches in chronic pain treatment
Time : 13:30-14:00
Biography:
A Alper Öztürk has completed his PhD from Anadolu University, Department of Pharmaceutical Technology in 2017. He has published more than 10 research articles about new drug delivery system and nanocarrier systems.
Abstract:
Nanotechnology is a frequently used approach to problem solving in disease treatment and it can be considered as a collection of tools and ideas that can be applied in the pharmaceutical technology. Chronic pain (CP) is generally known as any type of pain that lasts longer than 12 weeks. Drugs used to treat CP include analgesics such as opioids and nonsteroidal anti-inflammatory drug. Because of the low bioavailability of most drugs and/or the short half-life, the drugs in conventional treatment are not sufficient to treat CP. The development of new more effective therapeutic treatments for CP relief is essential for enhancing the patient quality of life and safety and avoiding or limiting risks of abuse, addiction or serious injuries posed by some of the present CP therapies. With this aim, several advanced Nanocarrier systems (NCSs) have been developed to increase bioavailability, therapeutic efficacy and safety. NCSs can be used effectively as a drug delivery system (DDS) with unique physicochemical-biological properties. The use of NCSs in the treatment of CP is one of the most popular research topics. For example, nanotechnology-based DDSs prepared with Eudragit&PLGA polymer of dexketoprofen trometamol that has a short-live, have entered the literature. Also, NCSs were prepared by using different polymers with flurbiprofen and ketoprofen lysine. When the results of the studies are examined, they are compared with the following results. Release rates of drugs with short half-lives were increased in vitro and in vivo. They concluded that side effects due to fluctuations in drug blood levels and toxicity, effective treatment and good patient compliance and the need for multiple dose regimens were eliminated, especially in oral administration. Nanotechnological DDSs capable of long-term drug release are new, important and promising systems for the treatment of CP with short half-life and low bioavailability drugs.
Alp Yildiz
Yildirim Beyazit University, Turkey
Title: Effect of oxidized regenerated cellulose application on post-trombectomy bleeding and pain
Time : 14:00-14:30
Biography:
Alp Yildiz born in Kutahya in 1983,has completed medical degree on Gazi University School of Medicine, has completed her PhD as General Surgery Specialist at 2015. He is one of the leading surgeons on colorectal surgery of a tertiary care university hospital in capital city Ankara. He has published more than 20 papers in reputed journals and has been serving as colorectal surgeon in Yildirim Beyazit University, Yenimahalle Training and Research Hospital.
Abstract:
Yildirim Beyazit University Yenimahalle Training and Research Hospital Ankara/Turkey. The aim of this study was to evaluate the effect of oxidized regenerated cellulose application on postoperative bleeding and pain after trombectomy for external trombosed hemorrhoids. After excluding patients with hemorrhagic disorder, chronic disease, and perianal abscess, trombectomy performed. After cleaning the area an elliptical incision made in the roof of the hemorrhoid, taking care to avoid the anal sphincter muscle and the incision directed radially from the anal orifice. After the thrombosed hemorrhoid unroofed, clot has removed and in Group-1 the cavity packed with Oxidized regerated cellulose(Oxicel ® Betatech Medical, Istanbul/Turkey), in Group-2 electrocauterised for hemostasis. The bleeding time and Pain was evaluated every day for 3 days postoperatively, and 10th day after the procedure. Secondary bleeding was reported at any time. A total of 21 patients in Group-1 (13 males, 8 females) between the ages of 24 and 54 years (mean age 43.46 ± 4.98) , a total of 14 patients in Group-2 (9 males, 5 females) (mean age 41.16 ± 3.75) were included in the study. Mean bleeding time showed no statistically significant difference between groups(p>0.05) The average pain score was greater in Group 2 than in Group 1 on each postoperative day (p < 0.05). Secondary bleeding was observed in 2 patients from Group-2. Oxicel application decreased pain levels while effectively controlling bleeding incidence during operation and the postoperative period.
Aybala Yildiz
Yildirim Beyazit University, Turkey
Title: Combination of irritable bowel syndrome with fibromyalgia and the effect of irritable bowel syndrome treatment on both
Time : 14:30-15:00
Biography:
Aybala Yildiz born in Ankara in 1981,has completed medical degree on Ankara University School of Medicine, has completed her PhD as General Surgery Specialist at 2010 and took the academical degree of associate professor at the age of 34. She is the leading surgeon of a tertiary care university hospital in capital city Ankara. She has published more than 30 papers in reputed journals and has been serving as a hospital board member of repute.
Abstract:
Few data are available to evaluate health-related quality of life of people with irritable bowel syndrome(IBS) and fewer data are available for anxiety and depression status in this patients. patients with IBS included the study. All patients has given 40 mg otilonium bromide-80 mg simeticone combination drug (Simflat®(Abdi Ä°brahim Pharmaceuticals, Ä°stanbul/Turkey)) in one tablet 3 times a day on meal time. Qol questionnaire(QoL), beck anxiety index (BAI), Hamilton depression index (HDI) and Fibromiyalgia symptom severity index(FMSS) applied before the treatment and after the treatment on follow-up at 3rd month. After the treatment BAI and HDI showed statistically significant improvement (p< 0.05) for all groups. BAI 6.98/3.11 and HDI 9.28/1.36 before and after treatment. Qol improved 48.87 to 77.77 (p< 0.05) and FMSS decreased 4.11 from 7.98 after treatment (p< 0.05). 64 patients of 114 showed complete recovery for both ibs and fibromyalgia after treatment (%56.14). In
the symptomatic treatment of Irritable Bowel Disease co-excistent with fibromyalgia, a major treatment alternative since being scientifically proven for their effectiveness for many years, Otilonium Bromide and Simethicone. On the other hand, when evaluated in respect to biotechnologic window ,this combination product with its unique approach as distinct from other drugs, has brought patient compliance into the forefront in chronic gas and dyspepsy affiliated with IBS which has problematic diagnose and treatment issues. This is why, it has been brought two different molecules which are used widespread but separately into a single tablet formulation: Otilonium Bromide with its spasmolytic, pain transmission reducing and antisecretory effects and Simethicone with its reducing effects on pain caused by excessive gas. Otilonium Bromide, which is in solid form and Simethicone which is in liquid form, are combined with the bilayer tablet technology by and presented to physicians in a single tablet as an innovative product. In the symptomatic treatment of Irritable Bowel Disease, a major treatment alternative since being scientifically proven for their effectiveness for many years, Otilonium Bromide and Simethicone's single tablet feature improves patient compliance of IBS patients and leads to improve the quality of life of IBS patients.
Sumithra Mohan
SRM College of Pharmacy, India
Title: Novel targets to neurological disorder - Alzheimer’s disease
Time : 15:00-15:30
Biography:
M. Sumithra , currently working as Associate Professor in SRM College of Pharmacy, SRMIST and has totally 12 years of teaching experience. Her Ph.D work focused on neuropharmacology with her specialization in Pharmacology. She has exposure on Alzheimer's disease, cancer studies and also perusing toxicological studies for formulations and phytomolecules. To her credit, she has presented papers in national and international conference and awarded Prize in AICTE sponsored National seminar and also awarded cash prize for PG research work. She has published 27 research and review articles in reputed National and
International Journals. She has guided 10 UG projects and 8 PG projects.
Abstract:
Neuropharmacology is a scientific study focused on the action of drugs used for psychiatric and neurodegenerative diseases. Neurological diseases occurs due to imbalance in molecular mechanism due to electrical and chemical signaling
disturbance. The primary focus on neuro pharmacological research is to develop novel targets to treat neurological disorders like schizophrenia, Parkinson's disease, epilepsy and hungintons disease. The prevalence of this disease varies from different regions of the country with a mean of 2394 per 1000000 population provided with rough estimation of 30 million people worldwide. Among the diseases, Alzheimer's and Parkinson's disease remains as great challenge in drug discovery. Alzheimer's disease is a neurodegenerative age related disease affecting the memory and disturbs visuospatial skills. Its hallmark includes hyper phosphorylation, glial activation, neurofibrillary tangles and amyloid plaques. Nowadays low educational status, occupational stress and inflammation leads to dementia and finally results in Alzheimer’s disease. On the other hand, genetic predisposition, long period uncontrolled cardiovascular disease, diabetes mellitus and dyslipidemia also promotes amyloid precursor protein formation resulting in Alzheimer's. Currently available drugs used for symptomatic relief but the etiology not cured. Novel approaches targeted to cure the etiology. Also the US FDA has approved few category of drugs which prevents beta-amyloid plaques and also hyper phosphorylation of proteins. The aim of this presentation is to highlight the current targets of this diseases and expected outcomes.
Break: Networking and Refreshment @ 15:30-16:00
Aseel Mahmoud
Liverpool John Moores University, UK
Title: Qualitative study of stakeholder’s perspectives on the current management and control of asthma patients in the North West of England
Time : 16:00-16:30
Biography:
Aseel Mahmoud has completed her Master degree in phrmaceutical sciences from Jordan University in Amman at 2013. In 2013 she joined Jordan University and worked as a part time teaching assisstant in the faculty of pharmacy. Then she joined Isra University in 2016. She holed a free lecturer position teaching pharmacy practice in the School of Pharmacy. Currently she is completing her PhD study in pharmacy practice in Liverpool John Moores University in the UK. Aseel is interested in research related to asthma services, pharmacy practice and multidisciplinary work.
Abstract:
Asthma is considered a public health problem, with an estimated 235 million people currently living with asthma globally, according to the World Health Organisation(1). However, there is a lack of evidence to inform the best way to organise structured asthma care in practice (2). In order to improve asthma management and control, the current levels of asthma control and management need to be evaluated in order to determine enablers for change. This study involved a total of 17 semistructured, face-to-face or telephone interviews with stakeholders including, for example: pharmacists and asthma consultant. Interview transcripts were analysed by thematic analysis. Seven key themes relating to asthma control and management were identified. Overall, participants felt that many adult asthma patients within their health care settings are poorly controlled and for several reasons including: poor inhaler technique, overtreatment and under treatment, poor medicine adherence – especially with preventer inhalers –, patient education and the current diagnosis pathway. The participants suggested that adult asthma patient treatment outcomes could be improved by providing better patient education, involving the patients in their treatment plan and improving the monitoring and diagnosis of asthma patients through multidisciplinary work. Interviewees felt that there were opportunities to utilise community pharmacy resources to improve asthma management and control by targeting certain adult asthma patient groups. The participants suggested many asthma patient groups, including for example: controlled asthma patients and young adult asthma patients. Further research will be performed to characterise asthma patient groups that could be targeted by community pharmacy and to develop a new care model for asthma patients.